Literature DB >> 15095302

Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa.

Katarzyna Szymańska1, Olufunmilayo A Lesi, Gregory D Kirk, Omar Sam, Philippe Taniere, Jean-Yves Scoazec, Maimuna Mendy, Marlin D Friesen, Hilton Whittle, Ruggero Montesano, Pierre Hainaut.   

Abstract

Hepatocellular carcinoma (HCC) is frequent in areas of high exposure to aflatoxin and high prevalence of HBV infection, such as western Africa and south-east China. A selective mutation in TP53 (AGG-->AGT at codon 249, Arg-->Ser) has been identified as a hotspot in HCCs from such areas, reflecting DNA damage caused by aflatoxin metabolites. Recent studies have shown that circulating free DNA can be retrieved from human plasma, and it is hypothesised that plasma DNA may serve as a source for biomarkers of tumorigenic processes. In our study, we have determined the prevalence of Ser-249 mutation, using a PCR-restriction digestion method, with selective use of short oligonucleotide mass spectrometry analysis (SOMA), in a series of 29 biopsy specimens of HCC from The Gambia in West Africa. Overall, we identified the Ser-249 mutation in 35% (10/29) of the tumours. In parallel, we tested 17 plasma samples from HCC patients with matching tumour tissue. The 249 status concordance between tumour tissues and matched plasma was 88.5%. These results indicate that the Ser-249 mutation is common in HCC in The Gambia (35%), although a higher prevalence has been reported in other regions with high population exposure to aflatoxin (e.g., eastern China: >50%). Moreover, our studies indicate that plasma is a convenient source of liver tumour-derived DNA, thus holding promise for earlier detection and diagnosis of cancer. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095302     DOI: 10.1002/ijc.20103

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

1.  Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas.

Authors:  Jingjing Jiao; Weibo Niu; Ying Wang; Keith Baggerly; Yuanqing Ye; Xifeng Wu; Dewitt Davenport; Jose Luis Almeda; Monica M Betancourt-Garcia; R Armour Forse; Heather L Stevenson; Gordon P Watt; Joseph B McCormick; Susan P Fisher-Hoch; Laura Beretta
Journal:  Cancer Prev Res (Phila)       Date:  2017-10-31

2.  DNA hybridization detection with 100 zM sensitivity using piezoelectric plate sensors with an improved noise-reduction algorithm.

Authors:  Ceyhun E Kirimli; Wei-Heng Shih; Wan Y Shih
Journal:  Analyst       Date:  2014-06-07       Impact factor: 4.616

Review 3.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

4.  Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells.

Authors:  Huai Wang; Peng Liao; Shelya X Zeng; Hua Lu
Journal:  Cancer Biol Ther       Date:  2019-11-21       Impact factor: 4.742

5.  Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids.

Authors:  Vaneet K Sharma; Paul Vouros; James Glick
Journal:  Int J Mass Spectrom       Date:  2011-07       Impact factor: 1.986

6.  Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.

Authors:  K L Aung; R E Board; G Ellison; E Donald; T Ward; G Clack; M Ranson; A Hughes; W Newman; C Dive
Journal:  Hugo J       Date:  2011-01-30

7.  WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.

Authors:  Ling Zhong; Lingling Wei; Jiao Chen; Xiaobing Huang; Yuping Gong; Yanrong Lu
Journal:  Mol Diagn Ther       Date:  2015-08       Impact factor: 4.074

Review 8.  Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma.

Authors:  Jian Zhou; Ao Huang; Xin-Rong Yang
Journal:  J Gastrointest Cancer       Date:  2016-06

Review 9.  Clinical outcomes and correlates of TP53 mutations and cancer.

Authors:  Ana I Robles; Curtis C Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03       Impact factor: 10.005

Review 10.  Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer.

Authors:  Ganepola Ap Ganepola; Joel Nizin; John R Rutledge; David H Chang
Journal:  World J Gastrointest Oncol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.